ANDAORAL-21TABLET1 Generic Approved
Approved
Jun 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
3/8 — Basic
AUROVELA 1.5/30 (norethindrone acetate and ethinyl estradiol) by Aurobindo Pharma is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 2017.
Drug data last refreshed 3d ago
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on AUROVELA 1.5/30 at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.